Sequenom Performs More than 1,000 T21 Tests, Reports 23 Percent Revenue Increase for 2011 | GenomeWeb

By Julia Karow

This story was originally published Jan 13.

Sequenom has reported results for more than 1,000 MaterniT21 prenatal Down syndrome tests since it launched it last fall, a company official said last week.

The company also reported a 23 percent increase in preliminary revenue for 2011, and expects to raise additional capital, probably in the first half of this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.